We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in the area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, oncology, urology, respiratory, vitamins and minerals, gastro intestinal, pain management, cardio-vascular, etc. primarily under the Lomotil, Lomofen+, Naprosyn, Azoran, Aldactone, and Serenace brand names. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
TODAY'S HIGH
515.7
TODAY'S LOW
504
52 WEEK HIGH
752.45
52 WEEK LOW
424.85
% of Shares Held by
All Insider
69.84%
% of Shares Held by
Institutions
5.11%
% of Float Held by
Institutions
16.96%
Number of Institutions
Holding Shares
2
MARKET CAP
846.21 Cr.
ETERPRISE VALUE
906.87 Cr.
NO. OF SHARES
1.65 Cr.
BOOK VALUE
141.325
DIV. YIELD
None%
DEBT
94 Lakhs
GROSS PROFIT
301.33 Cr.
CASH
70.26 Cr.
REVENUE
443.14 Cr.
REVENUE/SHARE
267.973
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | -11.97 Cr. | -11.97 Cr. | -11.97 Cr. | -11.97 Cr. |
| Change To Liabilities | -1.91 Cr. | 3.12 Cr. | 19.33 Cr. | -26.73 Cr. |
| Total cashflows from Investing Activities | -34.66 Cr. | -7.96 Cr. | -10.70 Cr. | -19.02 Cr. |
| Net Borrowings | -1.08 Cr. | -9.70 Cr. | -24.81 Cr. | -17.72 Cr. |
| Total Cash from Financing Activities | -13.51 Cr. | -10.49 Cr. | -39.30 Cr. | -26.50 Cr. |
| Other Liabilities | -1.35 Cr. | -1.15 Cr. | 7.40 Cr. | -15 Lakhs |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | 51.48 Cr. | 40 Cr. | 29.01 Cr. | 10.81 Cr. |
| Change in Cash | 16.58 Cr. | 39.82 Cr. | 17 Lakhs | 26 Lakhs |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | 64.75 Cr. | 58.27 Cr. | 50.17 Cr. | 45.78 Cr. |
| Depreciation | 15.66 Cr. | 15.73 Cr. | 15.57 Cr. | 14.57 Cr. |
| Other Cashflows from Investing Activities | 1.26 Cr. | 50 Lakhs | 50 Lakhs | 55 Lakhs |
| Dividends Paid | -11.91 Cr. | -11.91 Cr. | -10.59 Cr. | -3.97 Cr. |
| Change to Inventory | -24.66 Cr. | -11.72 Cr. | -5.57 Cr. | 12.65 Cr. |
| Change to Account Receivables | 24.81 Cr. | 6.22 Cr. | -23.53 Cr. | 28.60 Cr. |
| Other Cashflows from Financing Activities | -52 Lakhs | -79 Lakhs | -3.90 Cr. | -4.81 Cr. |
| Change to Net Income | 72 Lakhs | 5.33 Cr. | 7.17 Cr. | 5.28 Cr. |
| Capital Expenditures | -23.95 Cr. | -8.51 Cr. | -10.74 Cr. | -19.68 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 73.17 Cr. | 53.58 Cr. | 36.45 Cr. | 15.05 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 73.69 Cr. | 53.66 Cr. | 42.95 Cr. | 18.69 Cr. |
| Selling General Administrative | 99.97 Cr. | 102.75 Cr. | 99.27 Cr. | 98.81 Cr. |
| Gross Profit | 301.33 Cr. | 253.54 Cr. | 243.62 Cr. | 216.17 Cr. |
| Ebit | 73.69 Cr. | 53.66 Cr. | 42.95 Cr. | 18.69 Cr. |
| Operating Income | 73.69 Cr. | 53.66 Cr. | 42.95 Cr. | 18.69 Cr. |
| Other Operating Expenses | 112.01 Cr. | 80.66 Cr. | 85.04 Cr. | 83.74 Cr. |
| Interest Expense | -52 Lakhs | -79 Lakhs | -1.75 Cr. | -3.99 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 21.69 Cr. | 13.58 Cr. | 7.44 Cr. | 4.24 Cr. |
| Total Revenue | 443.15 Cr. | 389.14 Cr. | 375.57 Cr. | 330.16 Cr. |
| Total Operating Expenses | 369.46 Cr. | 335.48 Cr. | 332.62 Cr. | 311.47 Cr. |
| Cost of Revenue | 141.82 Cr. | 135.60 Cr. | 131.95 Cr. | 113.99 Cr. |
| Total Other Income Expense Net | -52 Lakhs | -8 Lakhs | -6.50 Cr. | -3.64 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 51.48 Cr. | 40 Cr. | 29.01 Cr. | 10.81 Cr. |
| Net Income Applicable to Common Shares | 51.48 Cr. | 40 Cr. | 29.01 Cr. | 10.81 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 34.68 Cr. | 37.13 Cr. | 41.87 Cr. | 52.18 Cr. |
| Capital Surplus | 0 | 34.46 Cr. | 34.46 Cr. | 34.46 Cr. |
| Total Liabilities | 88.84 Cr. | 86.94 Cr. | 90.16 Cr. | 90.74 Cr. |
| Stock Holder Equity | 255.77 Cr. | 216.45 Cr. | 176.57 Cr. | 160.50 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 33.97 Cr. | 17.79 Cr. | 15.35 Cr. | 14.39 Cr. |
| Total Assets | 344.61 Cr. | 303.39 Cr. | 266.73 Cr. | 251.24 Cr. |
| Common Stock | 13.23 Cr. | 13.23 Cr. | 13.23 Cr. | 13.23 Cr. |
| Retained Earnings | 0 | 168.71 Cr. | 128.83 Cr. | 112.76 Cr. |
| Other Liabilities | 8.43 Cr. | 6.51 Cr. | 6.05 Cr. | 6.34 Cr. |
| Good Will | 0 | 0 | 0 | 0 |
| Treasury Stock | 242.54 Cr. | 5 Lakhs | 5 Lakhs | 5 Lakhs |
| Other Assets | 2.93 Cr. | 2.47 Cr. | 8.08 Cr. | 9.34 Cr. |
| Cash | 70.26 Cr. | 40.36 Cr. | 54 Lakhs | 37 Lakhs |
| Current Liabilities | 80.11 Cr. | 79.69 Cr. | 82.59 Cr. | 77.82 Cr. |
| Long Term Asset Charges | 0 | 6 Lakhs | 4.60 Cr. | 6.18 Cr. |
| Short Long Term Debt | 28 Lakhs | 11 Lakhs | 4.44 Cr. | 20 Lakhs |
| Other Stockholder Equity | 242.54 Cr. | 5 Lakhs | 5 Lakhs | 5 Lakhs |
| Property Plant Equipment | 100.09 Cr. | 87.94 Cr. | 91 Cr. | 92.63 Cr. |
| Total Cur. Assets | 206.91 Cr. | 175.85 Cr. | 125.78 Cr. | 97.09 Cr. |
| Long Term Investments | 0 | 0 | 0 | 0 |
| Net Tangible Assets | 221.09 Cr. | 179.32 Cr. | 134.70 Cr. | 108.32 Cr. |
| Short Term Investments | 0 | 0 | 0 | 0 |
| Net Receivables | 33.01 Cr. | 61.85 Cr. | 66.92 Cr. | 42.38 Cr. |
| Long Term Debt | 1 Lakh | 8 Lakhs | 22 Lakhs | 4.63 Cr. |
| Inventory | 82.99 Cr. | 58.33 Cr. | 46.61 Cr. | 41.04 Cr. |
| Accounts Payable | 45.50 Cr. | 47.44 Cr. | 44.41 Cr. | 25.13 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account